DEFINITY

How to Use DEFINITY®: Dosing and Administration



DEFINITY vial

DEFINITY® - the only ultrasound enhancing agent with multiple dosing options to meet patient- and practice-specific needs4-6

A single vial of DEFINITY® is sufficient to capture essential diagnostic information1-3


Dosing and Administration Options

DILUTED BOLUS4

Diluted bolus is the most common DEFINITY® administration method and DEFINITY® is the only ultrasound enhancing agent approved for use in a diluted form.1-3 This efficient method simplifies administration by combining activated DEFINITY® and the preservative-free saline in the same syringe.
Diluted Bolus Method


CONTINUOUS INFUSION4

Continuous Infusion provides a consistent, steady enhancement of DEFINITY® and is well suited for exams which are performed over an extended period of time.
Continuous Infusion Method

 

BOLUS4

The Bolus method uses a weight-based dose of activated DEFINITY® followed by a saline flush. Weight-based dosing and administration is less commonly used.
Bolus Method

 

References
1.Becher H, Burns PN. Handbook of Contrast Echocardiography: Heidelberg, NY: Springer-Verlag; 2000:2-44.
2. Kitzman DW, Goldman ME, Gillam LD, Cohen JL, Aurigemma GP, Gottdiener JS. Efficacy and safety of the novel ultrasound contrast agent
perflutren (Definity) in patients with suboptimal baseline left ventricular echocardiographic images. Am J Cardiol. 2000;86(6):669-674.
3. Kurt M, Shaikh KA, Peterson L, et al. Impact of contrast echocardiography on evaluation of ventricular function and clinical management in a large prospective cohort. J Am Coll Cardiol. 2009;53(9):802-810.
4. DEFINITY® [package insert] N. Billerica MA: Lantheus Medical Imaging, Inc., 2017.
5. Optison™ [package insert]. Marlborough, MA: GE Healthcare, Inc.; 2016.
6. Lumason® [package insert], Monroe Twp., NJ: Bracco Diagnostics Inc., 2017.

INDICATIONS

Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

CONTRAINDICATIONS

Do not administer DEFINITY® to patients with known or suspected hypersensitivity to perflutren.

IMPORTANT SAFETY INFORMATION

WARNING:  Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration [see Warnings and Precautions (5.1)]. Most serious reactions occur within 30 minutes of administration.

  • Assess all patients for the presence of any condition that precludes DEFINITY® administration [see Contraindications (4)].

  • Always have resuscitation equipment and trained personnel readily available.


In postmarketing use, rare but serious cardiopulmonary or hypersensitivity reactions have been reported during or shortly following perflutren-containing microsphere administration [see Adverse Reactions (6)]. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions [see Adverse Reactions (6.2)]. It is not always possible to reliably establish a causal relationship to drug exposure due to the presence of underlying cardiopulmonary disease.

Please see full Prescribing Information, including boxed WARNING regarding serious cardiopulmonary reactions.

Lantheus Medical Imaging, Inc.
HOME Order